43.26
-0.25(-0.57%)
Currency In USD
| Previous Close | 43.51 |
| Open | 43.43 |
| Day High | 44.01 |
| Day Low | 42.22 |
| 52-Week High | 53.27 |
| 52-Week Low | 19.45 |
| Volume | 568,327 |
| Average Volume | 712,391 |
| Market Cap | 3.09B |
| PE | -12.4 |
| EPS | -3.49 |
| Moving Average 50 Days | 43.4 |
| Moving Average 200 Days | 38.53 |
| Change | -0.25 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,300.66 as of September 09, 2025 at a share price of $43.26. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $1,473.94 as of September 09, 2025 at a share price of $43.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
GlobeNewswire Inc.
Sep 03, 2025 11:00 AM GMT
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced th
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 11:00 AM GMT
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced tha
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
GlobeNewswire Inc.
Aug 04, 2025 11:00 AM GMT
WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second